Anavex Appoints Clinical Design Expert to Scientific Advisory Board

Anavex Appoints Clinical Design Expert to Scientific Advisory Board

NEW YORK, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.
("Anavex" or the "Company") (OTCQB:AVXL) today announced the appointment of
John Harrison, PhD, to its Scientific Advisory Board. Dr. Harrison is an
internationally acknowledged specialist for design of human clinical outcome
measurement in Alzheimer's disease and other cognitive impairments.

"Dr. Harrison brings an extensive experience in cognitive testing for clinical
trials to our Scientific Advisory Board," said Christopher U. Missling, PhD,
President and Chief Executive Officer of Anavex."I believe Dr. Harrison's
insight and guidance will contribute significantly to our trial design and
drug development initiatives, and I am delighted to welcome him to the Anavex

Dr. Harrison has successfully integrated cognitive testing into drug
development programs for many pharmaceutical and biotechnology companies
including eight of the current 'Fortune' top 10 pharmaceutical companies.He
is Honorary Senior Lecturer in the Department of Medicine at Imperial College
in London, focusing on investigating cognitive change that may show disease
progression in Alzheimer's and other related indications. Dr. Harrison is a
member of the American Psychological Association, holds Chartered Psychologist
status with the British Psychological Society and Chartered Scientist status
with the UK Science Council. He has authored/co-authored more than 60 books
and scientific articles and has been invited as a specialist for cognitive
tests at many international meetings, including the European Task Force for
Alzheimer's disease and American Alzheimer's Association roundtable events.

"Since being introduced to Anavex, it has become apparent to me how
potentially significant the Company's science could be for the future of
Alzheimer's and other CNS diseases," said Dr. Harrison."I am excited to apply
my area of interest, the measurement of cognitive change in clinical drug
trials, to the advancement of Anavex's promising pipeline and look forward to
serving on the Company's Scientific Advisory Board."

Dr. Harrison's background also includes prior positions as Head of
Neuropsychology at CeNeS Pharmaceuticals, Principal Consultant at CPC Pharma
Services, and Principal Scientist at CogState Ltd.In addition to his current
academic appointment, he is principal consultant at Metis Cognition Ltd and
holds a PhD in neuroscience from the University of London.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. ( is a clinical stage
biopharmaceutical company engaged in the development of novel drug candidates
to treat Alzheimer's, CNS diseases and various types of cancer. ANAVEX 2-73,
an orally available drug candidate developed to treat Alzheimer's through
potential disease modification, has undergone an initial Phase 1 human
clinical trial and was well tolerated in doses up to 55mg. Results from
pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and
neuroprotective properties.A highly encouraging synergistic effect has also
been observed between ANAVEX 2-73 and Aricept® (donepezil).The combined
therapeutics produced up to 80% greater reversal of memory loss in Alzheimer's
disease models versus when the drugs were used individually. Anavex is a
publicly traded corporation quoted as AVXL.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including the
risks set forth in the Company's most recent Annual Report on Form 10-K filed
with the SEC.Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement and Anavex Life Sciences Corp. undertakes no obligation to revise or
update this press release to reflect events or circumstances after the date

CONTACT: Anavex Life Sciences Corp.
         Research & Business Development
         Shareholder & Media Relations
         Toll-free: 1-866-505-2895
         Outside North America: +1 (416) 489-0092

Anavex Life Sciences Corp.
Press spacebar to pause and continue. Press esc to stop.